



LeanLife Health Inc.

380-580 Hornby Street
Vancouver, BC, V6C 3P6

NEWS RELEASE

LeanLife to Increase Production Capacity

VANCOUVER, British Columbia, November 25, 2019: [LeanLife Health Inc.](#) (CSE: LLP) (the “Company”) a Company focused on proprietary plant-based food products is pleased to announce that it is increasing its production capacity to meet anticipated demand for its Omega-3 product.

LeanLife previously sent samples of its plant-based Omega-3 product to numerous customers in Europe. At the request of some of those customers, LeanLife recently shipped additional samples in quantities sufficient for use in large volume production trials. Production trials follow after initial testing and satisfaction with the Product Specifications and Quality Certificate provided by LeanLife.

One of these food producers creates a variety of milk related products that are sold throughout Europe and through 500 stores in the United States.

With the potential for large scale demand of its product, LeanLife is upgrading its manufacturing equipment to increase its production capacity and build inventory to shorten the time period between future orders and delivery.

The upgraded reactor used in its proprietary process will increase LeanLife’s production capacity by 400% making a substantial improvement in throughput and order fulfillment. The new reactor will also result in reduced labour and cost of production thereby increasing profit margins for the company.

“The indications are that we will need to increase production capacity for 2020. We are therefore upgrading our facilities to put the company in a position to meet this potential customer demand for our plant-based Omega-3 product,” said Stan Lis, CEO.

About LeanLife Health and the Omega-3 Market

LeanLife Health’s products are **long-term shelf-stable** extractions from flax seed, a plentiful **plant-based source of Omega-3**, that give them a significant advantage as a fortified food ingredient.

Increased omega-3 intake, especially with LeanLife’s higher omega-3 to -6 ratio, has shown to have **significant health improvement impacts**.

LeanLife’s mission is to provide a relatively **low-cost means of replacing the less healthy vegetable oil in food**, and **transform them into healthier versions**.

“Improving the quality of food without requiring people to change what they eat is the best way to ensure they eat healthier and benefit from an improved quality of life.” – Stan Lis, CEO

LeanLife Health’s industry leading and **proprietary Omega-3 product formulations** are of the **highest quality** and **contain no cholesterol**. Products are available in oil, emulsion and powder forms.

The products can be used as **food additives** or as **nutraceuticals** and have been used to make bread, noodles, cheese, yogurt, juice and milk products for the European market.

The **global Omega-3 market** reached USD \$33 Billion in 2016 and is **expected to reach upwards of USD \$57 Billion by 2025**, according to a report by Grand View Research, Inc.

For more information, please contact:

Stan Lis, CEO
604-764-0518
SLis@LeanLifeHealth.com

Forward Looking Information

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control including, the Company's ability to compete with large food companies; sales of any potential products developed will be profitable; the ability to complete sales under the sales agreement. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

THE CSE HAS NEITHER APPROVED NOR DISAPPROVED THE INFORMATION CONTAINED HEREIN AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.